Phase 1b/2 two-part open label trial of ISA103 in combination with standard of care checkpoint blocker immunotherapies
Latest Information Update: 05 Jan 2023
At a glance
- Drugs ISA 103 (Primary) ; Immune checkpoint protein inhibitors
- Indications Uveal melanoma
- Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
- 05 Jan 2023 New trial record
- 04 Jan 2023 According to an ISA Pharmaceuticals media release, the ISA Pharmaceuticals and Cancer Focus Fund, LP is investing $5 million in funding to support this trial.
- 04 Jan 2023 According to an ISA Pharmaceuticals media release, the trial will be conducted at MD Anderson under the direction of Principal Investigator Sapna Patel.